| abstract |
The present invention relates to novel compounds, methods and compositions that increase the stability and / or activity of hypoxia-inducible factor (HIF) by being able to reduce the enzymatic activity of HIF hydroxylase. The present invention also provides a pharmaceutical composition comprising one or more compounds of formula I or II and a pharmaceutically acceptable excipient. In some embodiments, the composition further comprises at least one additional therapeutic agent or is used in combination with at least one additional therapeutic agent. In some embodiments, the agent is selected from the group consisting of vitamin B 12 , folic acid, ferrous sulfate, recombinant human erythropoietin and erythropoiesis stimulator (ESA). |